
-
Eli Lilly & Company NYSE:LLY Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Location: Lilly Corporate Center, Indianapolis, IN, 46285, United States | Website: https://www.lilly.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
684.1B
Cash
3.222B
Avg Qtr Burn
N/A
Short % of Float
0.82%
Insider Ownership
0.16%
Institutional Own.
84.03%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Jardiance® (empagliflozin) (anti-SGLT2) Details Diabetes, Type 2 diabetes, Chronic kidney disease | Approved Quarterly sales | |
Jaypirca (pirtobrutinib) Details Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma | Approved Quarterly sales | |
Omvoh® (mirikizumab) Details Crohns disease | Approved Quarterly sales | |
EBGLYSS™ (lebrikizumab-lbkz) Details Skin disease/disorder, Atopic dermatitis | Approved Quarterly sales | |
Jaypirca® Pirtobrutinib Details Cancer, Chronic lymphocytic leukemia, Lymphoma, Blood cancer, Small lymphocytic lymphoma | Approved Quarterly sales | |
Zepbound (Tirzepatide) Details Obstructive sleep apnea , Sleeping disorder | Approved Quarterly sales | |
Omvoh™ (mirikizumab-mrkz) Details Ulcerative colitis | Approved Quarterly sales | |
Zepbound (Tirzepatide) Details Obesity | Approved Quarterly sales | |
Kisunla (Donanemab) Details Alzheimer's disease | Approved Quarterly sales | |
Emgality® (galcanezumab-gnlm) Details Migraines | Phase 3 Data readout | |
Retevmo +/- pembrolizumab Details Non-small cell lung carcinoma | Phase 3 Data readout | |
Abemaciclib Details Castration-resistant prostate cancer | Phase 3 Data readout | |
Remternetug Details Alzheimer's disease | Phase 3 Data readout | |
Verzenio® (Abemaciclib ) Details Cancer, Breast cancer | Phase 3 Data readout | |
Imlunestrant (oral SERD) +/- Abemaciclib Details Cancer, Breast cancer | Phase 3 Data readout | |
Pirtobrutinib Details Blood cancer, Cancer, Lymphoma, Chronic lymphocytic leukemia | Phase 3 Data readout | |
Tirzepatide Details Heart failure, Obesity | Phase 3 Update | |
Orforglipron Details Type 1 diabetes | Phase 3 Update | |
Insulin efsitora alfa (efsitora) Details Type 2 diabetes, Diabetes | Phase 3 Update | |
Orforglipron Details Obesity | Phase 3 Update | |
Retevmo Details Medullary Thyroid Cancer | Phase 3 Update | |
Retatrutide Details Obesity | Phase 3 Initiation | |
MORF-057 (α4β7 integrin) Details Ulcerative colitis | Phase 2b Data readout | |
Phase 2b Update | ||
MORF-057 (α4β7 integrin) Details Crohns disease | Phase 2b Initiation | |
Tirzepatide Details metabolic dysfunction-associated steatohepatitis , Liver fibrosis | Phase 2 Update | |
Peresolimab /LY3462817 Details Autoimmune disease, Rheumatoid arthritis | Phase 2 Update | |
Mirikizumab (Pediatric) Details Ulcerative colitis | Phase 2 Update | |
Seasonal influenza mRNA vaccine Details Influenza | Phase 2 Update | |
Olomorasib +/- KEYTRUDA® (pembrolizumab) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
LY4170156 Details Advanced ovarian cancer, solid tumor/s | Phase 1 Data readout | |
LOXO-783 (PI3Ka Inhibitor) Details Cancer, Breast cancer | Phase 1 Data readout | |
DC-853 Details Inflammatory disease, Autoimmune disease | Phase 1 Update | |
AK-OTOF Details OTOF-mediated hearing loss | Phase 1 Update |